Harte Hanks (HHS) EBIAT (2016 - 2025)
Harte Hanks (HHS) has disclosed EBIAT for 16 consecutive years, with -$335000.0 as the latest value for Q2 2025.
- On a quarterly basis, EBIAT rose 98.8% to -$335000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was -$3.0 million, a 89.72% increase, with the full-year FY2024 number at -$30.3 million, down 1829.75% from a year prior.
- EBIAT was -$335000.0 for Q2 2025 at Harte Hanks, up from -$392000.0 in the prior quarter.
- In the past five years, EBIAT ranged from a high of $21.8 million in Q4 2022 to a low of -$27.8 million in Q2 2024.
- A 5-year average of $1.1 million and a median of $361000.0 in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: skyrocketed 1141.69% in 2022, then crashed 4898.97% in 2024.
- Harte Hanks' EBIAT stood at $1.8 million in 2021, then surged by 1141.69% to $21.8 million in 2022, then tumbled by 109.07% to -$2.0 million in 2023, then fell by 23.12% to -$2.4 million in 2024, then soared by 86.24% to -$335000.0 in 2025.
- Per Business Quant, the three most recent readings for HHS's EBIAT are -$335000.0 (Q2 2025), -$392000.0 (Q1 2025), and -$2.4 million (Q4 2024).